The utility of adenoviral vectors for gene therapy is currently limited due, in part, to the widespread distribution of the cellular receptor for the adenovirus fiber that precludes the targeting of specific cell types. In order to develop a targeted adenovirus, it is therefore necessary both to ablate endogenous viral tropism and to introduce novel tropism. We hypothesized that these two goals could be achieved by employing a neutralizing anti-fiber antibody, or antibody fragment, chemically conjugated to a cell-specific ligand. To test this concept, we chose to target the folate receptor, which is overexpressed on the surface of a variety of malignant cells. Therefore, we conjugated folate to the neutralizing Fab fragment of an anti-fiber monoclonal antibody. This Fab-folate conjugate was complexed with an adenoviral vector carrying the luciferase reporter gene and was shown to redirect adenoviral infection of target cells via the folate receptor at a high efficiency. Furthermore, when complexed with an adenoviral vector carrying the gene for herpes simplex virus thymidine kinase, the Fab-folate conjugate mediated the specific killing of cells that overexpress the folate receptor. This work thus represents the first demonstration of the retargeting of a recombinant adenoviral vector via a non-adenoviral cellular receptor.
Subscribe to Journal
Get full journal access for 1 year
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jolly, D. 1994. Viral vector systems for gene therapy. Cancer Gene Therapy 1: 51–64.
Trapnell, B. and Gorziglia, M. 1994. Gene therapy using adenoviral vectors. Curr. Opin. Biotech. 5: 617–625.
Stratford-Perricaudet, L., Makeh, I., Perricaudet, M. and Briand, P. 1992. Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90: 626–630.
Huard, J. et al. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 2: 107–115.
Herz, J. and Gerard, R. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA 90: 2812–2816.
Henry, L., Xia, D., Wilke, M., Deisenhofer, J. and Gerard, R. 1994. characterization of the knob domain of the adenovirus type 5 fiber protein expressed in E. coli . J. Virol. 68: 5239–5246.
Louis, N., Fender, P., Barge, A., Kitts, P. and Chroboczek, J. 1994. Cell-binding domain of adenovirus serotype 2 fiber. J. Virol. 68: 4104–4106.
Coney, L.R. et al. 1991. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51: 6125–6132.
Weitman, S. et al. 1992. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52: 3396–3401.
Ross, J.F., Chaudhuri, P.K. and Ratnam, M. 1994. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73: 2432–2443.
Weitman, S.D., Frazier, K.M. and Kamen, B.A. 1994. The folate receptor in central nervous system malignancies of childhood. J. Neuro Onc. 21: 107–112.
Leamon, C.P. and Low, P.S. 1992. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267: 24966–24971.
Gottschalk, S., Cristiano, R., Smith, L. and Woo, S. 1994. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Therapy 1: 185–191.
Kranz, D., Patrick, T., Brigle, K., Spinella, M. and Roy, E. 1995. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA 92: 9057–9061.
Lee, R.J. and Low, P.S. 1995. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233: 134–144.
Anderson, R., Kamen, B., Rothberg, K. and Lacey, S. 1992. Potocytosis: sequestration and transport of small molecules by caveolae. Science 255: 410–411.
FitzGerald, D., Padmanabhan, R., Pastan, I. and Willingham, M. 1983. Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 32: 607–617.
Varga, M., Weibull, C. and Everitt, E. 1991. Infectious entry pathway of adenovirus type 2. J. Virol. 65: 6061–6070.
Greber, U., Willetts, M., Webster, P. and Helenius, A. 1993. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75: 477–486.
Bai, M., Harfe, B. and Freimuth, P. 1993. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J. Virol. 67: 5198–5205.
Wickham, T., Mathias, P., Cheresh, D. and Nemerow, G. 1993. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 73: 309–319.
Elwood, P. 1989. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tisssue culture (KB) cells. J. Biol. Chem. 264: 14893–14901.
Kim, M. et al. 1996. Adenoviral vector mediated delivery of the herpes simplex virus thymidine kinase gene sensitizes EBV-transformed B cell lines to ganciclovir. Tumor Targeting. In press.
Moolten, F. 1986. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46: 5276–5281.
Rosenfeld, M. et al. 1995. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clinical Cancer Res. 1: 1571–1580.
Krasnykh, V., Mikheeva, G., Douglas, J. and Curiel, D. 1996. Generation of tropism-modified adenoviral vectors with modified fibers for altering viral tropism. J. Virol. 70: 6839–6846.
Roux, P., Jeanteur, P. and Piechaczyk, M. 1989. A versatile and potentially general approach to the targeting of specific cell types by retro-viruses: Application to the infection of human cells by means of major histocompatibilty complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc. Natl. Acad. Sci. USA 86: 9079–9083.
Russell, S., Hawkins, R. and Winter, G. 1993. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21: 1081–1085.
Kasahara, N., Dozy, A. and Kan, Y. 1994. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373–1376.
Cosset, F.-L. et al. 1995. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69: 6314–6322.
Michael, S. et al. 1993. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J. Biol. Chem. 268: 6866–6869.
Takeuchi, Y., Cosset, F.-L., Lachmann, P., Weiss, R. and Collins, M. 1994. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68: 8001–8007.
Douglas, J.T. and Curiel, D.T. 1995. Targeted gene therapy. Tumor Targeting 1: 67–84.
Graham, F., Smiley, J., Russell, W. and Nairn, R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59–72.
Graham, F. and Prevec, L. 1991. Manipulation of adenovirus vectors, pp. 109–128 in Methods in molecular biology Vol. 7, Gene transfer and expression techniques. Murray, E.J. and Walker, J.M. (eds.). Humana Press, Clifton.
Harlow, E. and Lane, D. 1988. Antibodies. A laboratory manual, Cold Spring Harbor Laboratory, New York.
About this article
Cite this article
Douglas, J., Rogers, B., Rosenfeld, M. et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14, 1574–1578 (1996). https://doi.org/10.1038/nbt1196-1574
FEBS Letters (2020)
Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line
Pathology & Oncology Research (2017)
Vaccine Engineering with Dual-Functional Mineral Shell: A Promising Strategy to Overcome Preexisting Immunity
Advanced Materials (2016)